| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MIF4GD |
| Uniprot No | A9UHW6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-222aa |
| 氨基酸序列 | MGEPSREEYK IQSFDAETQQ LLKTALKDPG AVDLEKVANV IVDHSLQDCV FSKEAGRMCY AIIQAESKQA GQSVFRRGLL NRLQQEYQAR EQLRARSLQG WVCYVTFICN IFDYLRVNNM PMMALVNPVY DCLFRLAQPD SLSKEEEVDC LVLQLHRVGE QLEKMNGQRM DELFVLIRDG FLLPTGLSSL AQLLLLEIIE FRAAGWKTTP AAHKYYYSEV SD |
| 预测分子量 | 25,4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MIF4GD重组蛋白的参考文献示例(注：MIF4GD相关研究较少，以下内容为模拟示例，供参考格式)：
1. **文献名称**：*Expression and functional characterization of recombinant MIF4G domain protein in inflammatory models*
**作者**：Smith A, et al.
**摘要**：本研究成功在大肠杆菌中表达并纯化了MIF4GD重组蛋白，验证其抑制巨噬细胞迁移的功能，并发现其通过调控TLR4信号通路减轻炎症反应。
2. **文献名称**：*Structural insights into the MIF4G domain of eukaryotic translation initiation factors*
**作者**：Chen L, et al.
**摘要**：通过X射线晶体学解析MIF4GD的三维结构，揭示其与RNA结合的关键位点，为设计靶向该结构域的抗病毒药物提供依据。
3. **文献名称**：*MIF4GD recombinant protein attenuates tumor growth by modulating angiogenesis*
**作者**：Wang Y, et al.
**摘要**：在结肠癌模型中，重组MIF4GD蛋白通过抑制VEGF通路显著降低肿瘤血管生成，提示其潜在抗肿瘤应用价值。
**注意**：若实际文献不足，建议扩展关键词(如“MIF4G domain”或“MIF structural domains”)或确认术语准确性。真实文献需通过PubMed/Google Scholar检索。
**Background on MIF4GD Recombinant Protein**
Macrophage Migration Inhibitory Factor (MIF) is a pleiotropic cytokine involved in regulating innate and adaptive immune responses. Initially identified for its role in inhibiting macrophage migration, MIF also exhibits pro-inflammatory functions, modulates cell proliferation, and influences apoptosis. It interacts with receptors such as CD74 and CXCRs, activating downstream pathways like MAPK and NF-κB. Dysregulated MIF expression is linked to autoimmune diseases, cancer progression, and chronic inflammatory conditions.
The MIF4GD recombinant protein refers to a genetically engineered variant of MIF, often designed to study specific functional domains or mutations. Recombinant MIF is typically produced using bacterial or mammalian expression systems, ensuring high purity and bioactivity for experimental use. The "4GD" designation may indicate a modified form, such as a point mutation (e.g., Cys60Ala) disrupting its tautomerase activity, or a truncated version targeting particular interaction sites.
Research on MIF4GD focuses on dissecting structure-function relationships, particularly its enzymatic activities and receptor-binding properties. Studies explore its role in disease models, such as sepsis, rheumatoid arthritis, and cancer, where MIF overexpression correlates with poor prognosis. Inhibiting MIF via recombinant mutants or neutralizing antibodies has therapeutic potential, prompting drug development efforts. Additionally, MIF4GD serves as a tool to investigate immune evasion mechanisms in pathogens, as some microbes produce MIF homologs to modulate host responses.
Overall, MIF4GD recombinant protein is a critical reagent for advancing understanding of MIF's multifaceted roles and translating insights into targeted therapies for inflammation-related disorders.
×
